United States - English - NLM (National Library of Medicine)

colgate-palmolive company - sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - anticavity helps protect against cavities

United States - English - NLM (National Library of Medicine)

colgate-palmolive company - sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - anticavity helps protect against cavities

United States - English - NLM (National Library of Medicine)

colgate-palmolive company - sodium monofluorophosphate (unii: c810jcz56q) (fluoride ion - unii:q80vpu408o) - anticavity helps protect against cavities

United States - English - NLM (National Library of Medicine)

colgate-palmolive company - sodium monofluorophosphate (unii: c810jcz56q) (fluoride ion - unii:q80vpu408o) - anticavity helps protect against cavities

Ireland - English - HPRA (Health Products Regulatory Authority)

bioglan laboratories ltd - betaine hydrochloride sodium bicarbonate dimethicone 350 - granules effervescent

Ireland - English - HPRA (Health Products Regulatory Authority)

nicholas laboratories - dimethicone 350 betaine hydrochloride sodium bicarbonate - gel

United States - English - NLM (National Library of Medicine)

novitium pharma llc - betaine (unii: 3scv180c9w) (betaine - unii:3scv180c9w) - betaine anhydrous for oral solution is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations in pediatric and adult patients.  included within the category of homocystinuria are  - cystathionine beta-synthase (cbs) deficiency - 5,10-methylenetetrahydrofolate reductase (mthfr) deficiency  - cobalamin cofactor metabolism (cbl) defect  none risk summary  available data from a limited number of published case reports and post marketing experience with betaine anhydrous for oral solution use in pregnancy have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with betaine. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of majo

United States - English - NLM (National Library of Medicine)

oakrum pharma, llc - betaine (unii: 3scv180c9w) (betaine - unii:3scv180c9w) - betaine anhydrous for oral solution is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations in pediatric and adult patients. included within the category of homocystinuria are - cystathionine beta-synthase (cbs) deficiency - 5,10-methylenetetrahydrofolate reductase (mthfr) deficiency - cobalamin cofactor metabolism (cbl) defect none. risk summary available data from a limited number of published case reports and post marketing experience with betaine anhydrous for oral solution use in pregnancy have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with betaine. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects

United States - English - NLM (National Library of Medicine)

lukare medical, llc - betaine (unii: 3scv180c9w) (betaine - unii:3scv180c9w) - betaine anhydrous for oral solution is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations in pediatric and adult patients. included within the category of homocystinuria are: none. risk summary available data from a limited number of published case reports and postmarketing experience with betaine anhydrous for oral solution use in pregnancy have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with betaine. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. risk summary there are no data on the presence of betaine in hum

United States - English - NLM (National Library of Medicine)

cosette pharmaceuticals, inc. - betaine (unii: 3scv180c9w) (betaine - unii:3scv180c9w) - betaine anhydrous for oral solution is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations in pediatric and adult patients. included within the category of homocystinuria are - cystathionine beta-synthase (cbs) deficiency - 5,10-methylenetetrahydrofolate reductase (mthfr) deficiency - cobalamin cofactor metabolism (cbl) defect none. risk summary available data from a limited number of published case reports and post marketing experience with betaine anhydrous for oral solution use in pregnancy have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with betaine. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and